Advertisement
AIMD vs CRMD
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AIMD is a StrongBuy and CRMD is a StrongBuy.
AIMD's Stochastic Oscillator is remaining in oversold zone for 10 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
Following a +6.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where AIMD advanced for three days, in 147 of 186 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
AIMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for AIMD turned negative on September 25, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 40 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AIMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for AIMD entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.979) is normal, around the industry mean (1.792). P/E Ratio (-0.353) is within average values for comparable stocks, (7.746). Projected Growth (PEG Ratio) (0.120) is also within normal values, averaging (5.470). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. AIMD's P/S Ratio (588.235) is very high in comparison to the industry average of (32.028).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. AIMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AIMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.
CRMD sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for CRMD moved above the 200-day moving average on October 14, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CRMD's RSI Indicator exited the oversold zone, 27 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on CRMD as a result. In 67 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for CRMD just turned positive on October 15, 2026. Looking at past instances where CRMD's MACD turned positive, the stock continued to rise in 32 of 41 cases over the following month. The odds of a continued upward trend are 78%.
Following a +5.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRMD advanced for three days, in 227 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
CRMD moved below its 50-day moving average on September 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CRMD crossed bearishly below the 50-day moving average on September 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
CRMD broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CRMD entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 19 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. CRMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 80 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.318) is normal, around the industry mean (2.988). P/E Ratio (3.167) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (5.636) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (1.564) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
AIMD | CRMD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 92 | 43 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 90 Overvalued | 87 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 80 | |
SMR RATING 1..100 | 100 | 19 | |
PRICE GROWTH RATING 1..100 | 92 | 60 | |
P/E GROWTH RATING 1..100 | 10 | 96 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CRMD's Valuation (87) in the Medical Specialties industry is in the same range as AIMD (90) in the null industry. This means that CRMD’s stock grew similarly to AIMD’s over the last 12 months.
CRMD's Profit vs Risk Rating (80) in the Medical Specialties industry is in the same range as AIMD (100) in the null industry. This means that CRMD’s stock grew similarly to AIMD’s over the last 12 months.
CRMD's SMR Rating (19) in the Medical Specialties industry is significantly better than the same rating for AIMD (100) in the null industry. This means that CRMD’s stock grew significantly faster than AIMD’s over the last 12 months.
CRMD's Price Growth Rating (60) in the Medical Specialties industry is in the same range as AIMD (92) in the null industry. This means that CRMD’s stock grew similarly to AIMD’s over the last 12 months.
AIMD's P/E Growth Rating (10) in the null industry is significantly better than the same rating for CRMD (96) in the Medical Specialties industry. This means that AIMD’s stock grew significantly faster than CRMD’s over the last 12 months.
| AIMD | CRMD | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 85% | 2 days ago 87% |
| Stochastic ODDS (%) | 2 days ago 89% | 2 days ago 87% |
| Momentum ODDS (%) | N/A | 2 days ago 76% |
| MACD ODDS (%) | 2 days ago 85% | 2 days ago 78% |
| TrendWeek ODDS (%) | 2 days ago 88% | 2 days ago 79% |
| TrendMonth ODDS (%) | 2 days ago 88% | 2 days ago 80% |
| Advances ODDS (%) | 21 days ago 79% | 2 days ago 81% |
| Declines ODDS (%) | 2 days ago 90% | 21 days ago 85% |
| BollingerBands ODDS (%) | 2 days ago 89% | 2 days ago 81% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 83% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AIMD’s FA Score shows that 1 FA rating(s) are green while CRMD’s FA Score has 1 green FA rating(s).
- AIMD’s FA Score: 1 green, 4 red.
- CRMD’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AIMD’s TA Score shows that 4 TA indicator(s) are bullish while CRMD’s TA Score has 5 bullish TA indicator(s).
- AIMD’s TA Score: 4 bullish, 3 bearish.
- CRMD’s TA Score: 5 bullish, 6 bearish.
Price Growth
AIMD (@Electronic Equipment/Instruments) experienced а -8.32% price change this week, while CRMD (@Biotechnology) price change was +5.41% for the same time period.
The average weekly price growth across all stocks in the @Electronic Equipment/Instruments industry was -3.39%. For the same industry, the average monthly price growth was -13.90%, and the average quarterly price growth was -16.41%.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
Reported Earning Dates
AIMD is expected to report earnings on Nov 12, 2026.
CRMD is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Electronic Equipment/Instruments (-3.39% weekly)This industry manufactures electronic products used in various critical and sophisticated technologies, including laser-based systems, circuit and continuity testers, electro-optical measuring instruments and high-speed precision weighing and inspection equipment. Some major companies operating in this business are Canon Inc., Keysight Technologies Inc., and Fortive Corp.
@Biotechnology (-1.10% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
AIMD and
Correlation & Price change
A.I.dvisor tells us that AIMD and AGPU have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AIMD and AGPU's prices will move in lockstep.
| Ticker / NAME | Correlation To AIMD | 1D Price Change % | ||
|---|---|---|---|---|
| AIMD | 100% | -2.24% | ||
| AGPU - AIMD | 30% Poorly correlated | +5.90% | ||
| KEYS - AIMD | 30% Poorly correlated | +2.15% | ||
| CODX - AIMD | 30% Poorly correlated | -0.82% | ||
| MBOT - AIMD | 29% Poorly correlated | -0.78% | ||
| CRMD - AIMD | 28% Poorly correlated | +2.91% | ||
More | ||||